Response to systemic therapy in fumarate hydratase-deficient renal cell carcinoma.

[1]  R. Motzer,et al.  Comprehensive Molecular Characterization and Response to Therapy in Fumarate Hydratase–Deficient Renal Cell Carcinoma , 2021, Clinical Cancer Research.

[2]  I. Thompson,et al.  A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial , 2021, The Lancet.

[3]  M. Atkins,et al.  Open-Label, Single-Arm, Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Non–Clear Cell Renal Cell Carcinoma , 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  A. Ravaud,et al.  Are immune checkpoint inhibitors a valid option for papillary renal cell carcinoma? A multicentre retrospective study. , 2020, European journal of cancer.

[5]  S. Signoretti,et al.  Efficacy of Savolitinib vs Sunitinib in Patients With MET-Driven Papillary Renal Cell Carcinoma , 2020, JAMA oncology.

[6]  Mark W. Ball,et al.  Results from a phase II study of bevacizumab and erlotinib in subjects with advanced hereditary leiomyomatosis and renal cell cancer (HLRCC) or sporadic papillary renal cell cancer. , 2020, Journal of Clinical Oncology.

[7]  N. Rioux-Leclercq,et al.  Axitinib in first-line for patients with metastatic papillary renal cell carcinoma: Results of the multicentre, open-label, single-arm, phase II AXIPAP trial. , 2020, European journal of cancer.

[8]  T. Powles,et al.  Overall survival results for durvalumab and savolitinib in metastatic papillary renal cancer. , 2020 .

[9]  Chad A. LaGrange,et al.  NCCN Guidelines Insights: Kidney Cancer, Version 2.2020. , 2019, Journal of the National Comprehensive Cancer Network : JNCCN.

[10]  M. Zhou,et al.  A Clinicopathologic and Molecular Analysis of Fumarate Hydratase-deficient Renal Cell Carcinoma in 32 Patients , 2019, The American journal of surgical pathology.

[11]  H. Zeng,et al.  Fumaratehydratase-deficient renal cell carcinoma: a clinicopathological and molecular study of 13 cases , 2019, Journal of Clinical Pathology.

[12]  B. Keam,et al.  Bevacizumab Plus Erlotinib Combination Therapy for Advanced Hereditary Leiomyomatosis and Renal Cell Carcinoma-Associated Renal Cell Carcinoma: A Multicenter Retrospective Analysis in Korean Patients , 2019, Cancer research and treatment : official journal of Korean Cancer Association.

[13]  T. Powles,et al.  Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal‐Cell Carcinoma , 2019, The New England journal of medicine.

[14]  Chad A. LaGrange,et al.  NCCN Guidelines Insights: Hodgkin Lymphoma, Version 1.2018. , 2018, Journal of the National Comprehensive Cancer Network : JNCCN.

[15]  E. Jonasch,et al.  Cabozantinib for the treatment of patients with metastatic non-clear cell renal cell carcinoma: A retrospective analysis. , 2018, European journal of cancer.

[16]  N. Agarwal,et al.  Cabozantinib (Cabo) in advanced non-clear cell renal cell carcinoma (nccRCC): A retrospective multicenter analysis. , 2018 .

[17]  Bohuslav Melichar,et al.  Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal‐Cell Carcinoma , 2018, The New England journal of medicine.

[18]  C. Genestie,et al.  Pattern multiplicity and fumarate hydratase (FH)/S-(2-succino)-cysteine (2SC) staining but not eosinophilic nucleoli with perinucleolar halos differentiate hereditary leiomyomatosis and renal cell carcinoma-associated renal cell carcinomas from kidney tumors without FH gene alteration , 2018, Modern Pathology.

[19]  C. Genestie,et al.  Reassessing the clinical spectrum associated with hereditary leiomyomatosis and renal cell carcinoma syndrome in French FH mutation carriers , 2017, Clinical genetics.

[20]  J. Šufliarský,et al.  Crizotinib achieves long-lasting disease control in advanced papillary renal-cell carcinoma type 1 patients with MET mutations or amplification. EORTC 90101 CREATE trial. , 2017, European journal of cancer.

[21]  T. Powles,et al.  Biomarker-Based Phase II Trial of Savolitinib in Patients With Advanced Papillary Renal Cell Cancer. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  C. Porta,et al.  Open-label phase 2 trial of first-line everolimus monotherapy in patients with papillary metastatic renal cell carcinoma: RAPTOR final analysis. , 2016, European journal of cancer.

[23]  Steven J. M. Jones,et al.  Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma. , 2016, The New England journal of medicine.

[24]  M. Stoppelli,et al.  Reversal of Warburg Effect and Reactivation of Oxidative Phosphorylation by Differential Inhibition of EGFR Signaling Pathways in Non–Small Cell Lung Cancer , 2015, Clinical Cancer Research.

[25]  A. Ravaud,et al.  First-line treatment with sunitinib for type 1 and type 2 locally advanced or metastatic papillary renal cell carcinoma: a phase II study (SUPAP) by the French Genitourinary Group (GETUG). , 2015 .

[26]  W. Linehan,et al.  Hereditary leiomyomatosis and renal cell cancer (HLRCC): renal cancer risk, surveillance and treatment , 2014, Familial Cancer.

[27]  W Marston Linehan,et al.  Molecular Pathways: Fumarate Hydratase-Deficient Kidney Cancer—Targeting the Warburg Effect in Cancer , 2013, Clinical Cancer Research.

[28]  Keith T Flaherty,et al.  Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  W. Linehan,et al.  A phase II study of bevacizumab and erlotinib in subjects with advanced hereditary leiomyomatosis and renal cell cancer (HLRCC) or sporadic papillary renal cell cancer (RCC). , 2012 .

[30]  L. Thomas,et al.  Novel FH mutations in families with hereditary leiomyomatosis and renal cell cancer (HLRCC) and patients with isolated type 2 papillary renal cell carcinoma , 2011, Journal of Medical Genetics.

[31]  W. Linehan,et al.  Fumarate hydratase enzyme activity in lymphoblastoid cells and fibroblasts of individuals in families with hereditary leiomyomatosis and renal cell cancer , 2006, Journal of Medical Genetics.

[32]  A. Paetau,et al.  Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer , 2002, Nature Genetics.

[33]  The Multiple Leiomyoma Consortium.  Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer , 2002 .